论文部分内容阅读
目的:探讨乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、c-erbB-2、p53癌基因表达及其与淋巴结转移、临床分期的关系.方法:采用免疫组织化学技术s-p法检测80例乳腺癌组织中c-erbB-2、p53、ER、PR的表达.结果:c-erbB-2、p53、ER、PR的阳性率分别为:48.75%(39/80)、56.25%(45/80)、52.5%(42/80)、58.75%(47/80);c-erbB-2、p53在ER、PR均阳性组的表达低于二者均阴性组的表达(p<0.05);c-erbB-2、p53在淋巴结转移组中表达高于淋巴结未转移组的表达(p<0.05);ER与PR的表达呈显著相关性,与临床分期及组织学类型无关.结论:c-erbB-2、p53、ER、PR与乳腺癌的发生发展有关,是指导内分泌治疗的重要指标,有利于客观评估乳腺癌的生物学行为,判定预后.
Objective: To investigate the relationship between estrogen receptor (ER), progesterone receptor (PR), c-erbB-2 and p53 oncogene expression and lymph node metastasis and clinical stage in breast cancer.Methods: Immunohistochemistry The expression of c-erbB-2, p53, ER and PR in 80 cases of breast cancer tissues were detected by SP method.Results: The positive rates of c-erbB-2, p53, ER and PR were 48.75% (39/80) , 56.25% (45/80), 52.5% (42/80) and 58.75% (47/80), respectively. The expression of c-erbB-2 and p53 in both ER and PR positive groups was lower than that in both negative and negative groups (p <0.05). The expression of c-erbB-2 and p53 in lymph node metastasis group was higher than that in lymph node metastasis group (p <0.05). The expression of ER and PR was significantly correlated with clinical stage and histological type No correlation.Conclusion: The expression of c-erbB-2, p53, ER and PR is related to the occurrence and development of breast cancer, which is an important index to guide the endocrine therapy, which is helpful to objectively evaluate the biological behavior of breast cancer and to judge the prognosis.